Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 17/20 | 1.00 |
| ▸ | QDPR | P09417 | 1/20 | 0.60 |
| ▸ | CHUK | O15111 | 1/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29682880 | 0.86 | ERN1 (0.74) | ERN1 | |
| SCHEMBL24086095 | 0.86 | ERN1 (0.74) | ERN1 | |
| SCHEMBL31398624 | 0.85 | ERN1 (0.74) | ERN1QDPRCHUKCYP17A1CYP3A4 | |
| SCHEMBL6640732 | 0.82 | ERN1 (0.70) | ERN1 | |
| SCHEMBL30554383 | 0.82 | ERN1 (0.69) | ERN1 | |
| SCHEMBL30554384 | 0.82 | ERN1 (0.69) | ERN1 | |
| SCHEMBL29751505 | 0.82 | ERN1 (0.69) | ERN1 | |
| SCHEMBL26606756 | 0.82 | ERN1 (0.69) | ERN1 | |
| SCHEMBL30362773 | 0.81 | ERN1 (0.71) | ERN1 | |
| SCHEMBL1711118 | 0.81 | ERN1 (0.71) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118108661-B | Diamine monomer with nitrogen heterocycle and benzocyclobutene structure, and preparation method and application thereof | 波米科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118125972-B | Diamine monomer with nitrogen heterocycle and benzocyclobutene structure, and preparation method and application thereof | 波米科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118125972-A | Diamine monomer with nitrogen heterocycle and benzocyclobutene structure, and preparation method and application thereof | 波米科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118108661-A | Diamine monomer with nitrogen heterocycle and benzocyclobutene structure, and preparation method and application thereof | 波米科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-108503848-B | Salen-Rh (II) coordination polymer and preparation method and application thereof | 邯郸学院 | 2020-09-22 | — | — | CN | disclosed |
| US-9981901-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-9981901-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
| EP-3150589-A1 | IRE-1A INHIBITORS | MannKind Corporation (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2008057468-A1 | SMALL ORGANIC MOLECULE REGULATORS OF CELL PROLIFERATION | CURIS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080058521-A1 | Processes for the preparation of compounds | WYETH (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058521-A1 | Processes for the preparation of compounds | WYETH (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058521-A1 | Processes for the preparation of compounds | WYETH (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2007089669-A2 | PROCESSES FOR THE PREPARATION OF COMPOUNDS WHICH MODULATE CELL PROLIFERATION | WYETH (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1412327-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG Biomedical Institute (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-11-06 | — | — | US | disclosed |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| WO-2002096867-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG BIOMEDICAL INSTITUTE (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152206-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | ERN1 3/4885QDPR 3619/4885CHUK 203/4885 |
| US-20080058521-A1 | Processes for the preparation of compounds | MKI67, MCL1, DCX | ERN1 2740/4885QDPR 758/4885CHUK 805/4885 |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | ERN1 446/4885QDPR 1963/4885CHUK 121/4885 |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | ERN1 446/4885QDPR 1963/4885CHUK 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.